Skip to content

Randomized comparative clinical study of efficacy of guda pippalimoola churna and tagara churna in anidra with special reference to primary insomnia

Randomized comparative clinical study of efficacy of Guda Pippalimoola Churna and Tagara Churna in Anidra with special reference to Primary Insomnia - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092557
Enrollment
120
Registered
2025-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system

Interventions

None listed

Sponsors

Aditi Sandip Suvase
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient whose informed written consent has been taken 2.Patients of age group 20-60 years 3. Patients suffering from sign and symptoms of Anidra such as jrumbha,tandra,angamarda,shirogaurav,smritidourbalya,manodourbalya 4. Patients having Insomnia Severity Index more than 7 5. Patients who are suffering from difficulty to initiate or maintaing sleep or non restorative sleep for at least 1 month i.e.primary insomnia 6. Patients who are suffering from negative condition to sleep environment i.e.psychophysiolgic insomnia

Exclusion criteria

Exclusion criteria: 1. Patients having insomnia due to severe illness such as cardiac diseases, hypertension, diabetes and other chronic disorders like bronchial asthma,malignancies,liver diseases,chronic renal diseases were excluded from the study 2. Patients with secondary insomnia , alcoholism, exaggeration of previous psychiatric illness (major depression and mania), narcolepsy, breathing related sleep disorder, schizophrenia 3.Patient having night shift duties 4.Pregnant woman and planning to be pregnant in future 6 months or lactating mothers 5.Patient not willing to participate in the clinical trial or written consent

Design outcomes

Primary

MeasureTime frame
Improvement in nidraTimepoint: In 28 days

Secondary

MeasureTime frame
Decrease in symptoms of anidraTimepoint: 28 Days

Countries

India

Contacts

Public ContactDr Pallavi Muneshwar

SSTAC Sangamner

pallavi.eml@gmail.com9975229605

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026